Compare McCormick & Company, Incorporated (MKC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Pfizer Inc — how do they compare? McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B), while Pfizer Inc trades at $28.24 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 12.8× McCormick & Company, Incorporated's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Pfizer Inc for 158 Days on average.
| MKC | PFE | |
|---|---|---|
Market Cap | $12.39B | $158.56B |
Volume | 6,140,872 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $29.02 |
52-Week Low | $44.14 | $23.67 |
Typical Hold Time | 67 Days | 158 Days |
Enterprise Value | $17.07B | $210.06B |
Dividend Yield | 4.18% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.005, down 0.54% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q3 2026 results with 17% sales growth and margin expansion, supported by the McCormick de Mexico acquisition. Valuation metrics appear attractive with a P/E of 8.31 and net income margin of 19.39%, while analyst consensus shows a mixed but predominantly hold rating.
The stock presents value opportunities with below-sector P/E ratios and consistent dividend payments, but faces technical headwinds and competitive pressures. Upside potential exists toward the $53.50 consensus target, though investors should monitor integration execution and consumer spending trends given the bearish technical indicators and mixed analyst sentiment.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
